Ann: December 2021 Quarterly Update and Appendix 4C, page-3

Did everybody notice the bonus news outside of the reporting timeframe in this quarterly report?

I wonder if this could have been better served as an independent announcement to the quarterly? It's fantastic news and hopefully the ASX would have assigned it as price-sensitive had it been independently announced.

This approval must be huge news for any planned optimization trials ready to go ahead! We can now proceed to the clinic!

The update read,

"Developments after the reporting period After the reporting period, Prescient received accreditation by the Office of the Gene Regulator (OTGR) to enable clinical studies for OmniCAR. The OTGR accreditation is separate from approval by the Therapeutics Goods Administration. Under the Gene Technology Act 2000, the Instrument of Accreditation is a requirement to enable a company to conduct clinical trials in Australia involving gene-edited cells, such as CAR-T therapies. Prescient Managing Director and CEO Steven Yatomi-Clarke said, "This OGTR accreditation is an important step in the regulatory process to conduct a CAR-T trial in Australia. In addition to our research and development, Prescient is undertaking a significant body of regulatory work as we progress the OmniCAR programs towards clinical trials.”